The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Managing multiple myeloma patients with del(17p)
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, outlines treatment options for patients with multiple myeloma with 17p deletion, highlighting key clinical trials. Numerous studies have demonstrated that this patient population has a poorer prognosis compared to other patients with multiple myeloma. The HOVON-65/GMMG-HD4 study (EudraCT 2004-000944-26) and the TOURMALINE-MM1 study (NCT01564537) have reported a survival benefit for patients with del(17p) receiving continuous bortezomib treatment and ixazomib in combination with lenalidomide and dexamethasone respectively, suggesting the combination of a proteasome inhibitor with an immunomodulatory agent as a promising treatment option for these patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
